Swastham Appoints Dr. Sunil Deshmukh and Rich Brady to Leadership Roles
News related to:Swastham · 2 min read
SAN DIEGO, CA, UNITED STATES, November 11, 2026 /CourierPR/ -- Swastham, an AI-driven health technology platform, has appointed Dr. Sunil Deshmukh to its board of directors and Rich Brady as a strategic board advisor. These appointments aim to bolster the company’s strategic leadership as it advances its mission of making lifestyle medicine accessible through artificial intelligence.
Dr. Sunil Deshmukh, with over 30 years of international leadership experience, will serve on the board of directors of Sucheta Swastham Private Limited in India. Deshmukh has held senior leadership positions with organizations such as AM International Holdings, Singapore, Indo-Jordan Chemicals, McDonald's India, and Foster's India. He currently serves as Co-President of EMCC Asia Pacific, Global Board Director of the Institute of Management Accountants (IMA), and Managing Partner of Sunil Deshmukh C-Suite Lab.
Dr. Deshmukh will leverage his extensive experience in global business operations, board governance, and strategic leadership to support Swastham in strengthening its organizational foundations, expanding its partnerships, and pursuing sustainable international growth.
Rich Brady, a retired U.S. Marine Corps Colonel, brings a distinguished background in financial management, strategy, and organizational leadership. He currently serves as CEO of the Society of Defense Financial Management, a global professional association focused on advancing financial excellence across the defense sector. Brady will serve as a strategic board advisor to Swastham, Inc., USA. His experience leading complex organizations and navigating strategic challenges will guide Swastham as it builds the foundation for long-term growth.
Swastham is focused on building an AI-powered platform that enables health experts to transform their proven lifestyle medicine protocols into personalized digital care programs. The platform combines expert-developed knowledge, governed AI, human expert oversight, and continuous user engagement to expand access to lifestyle-based care for chronic conditions and other health challenges. The company is initially focused on metabolic and musculoskeletal health, including diabetes, obesity, and joint and muscle health, with a broader vision of expanding access to evidence-based lifestyle medicine globally.
With these appointments, Swastham continues to strengthen its leadership and governance as it prepares for the next phase of platform development, strategic partnerships, and market expansion.